WIRE — El tratamiento experimental combina tres vías hormonales, frente a las dos de Zepbound y ha mostrado una mayor potencia para reducir peso. Analistas esperan que alcance ventas cercanas a US$ 16 mil millones en 2036.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.